Brief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
01/07/2024 15:07
July 1 (Reuters) - TRACON Pharmaceuticals Inc TCON.PK :
* TRACON PHARMACEUTICALS ANNOUNCES TERMINATION OF ENVASARC
TRIAL
AND WILL EXPLORE STRATEGIC ALTERNATIVES LEVERAGING ITS IN-HOUSE
PRODUCT DEVELOPMENT PLATFORM
* TRACON PHARMACEUTICALS INC - TO FOCUS ON EXPLORING
STRATEGIC
ALTERNATIVES
* TRACON PHARMACEUTICALS INC - ENVASARC TRIAL ORR IS 5%,
DOES NOT
MEET 11% ENDPOINT
* TRACON PHARMACEUTICALS INC - TO REDUCE CASH BURN
IMMEDIATELY
Source text for Eikon: ID:nGNX8FRqh6
Further company coverage: TCON.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants